Patrick W. Serruys works in Interventional / Structural Cardiology affiliated with Ollscoil na Gaillimhe – University of Galway.
Professor Patrick W. Serruys is Established Professor of Interventional Medicine and Innovation at the University of Galway, Ireland, and Senior Consultant at the CORRIB Research Centre for Advanced Imaging and Core Laboratory. He has over four decades of experience leading clinical trials and pioneering interventional procedures and devices. He previously served as Head of the Interventional Cardiology Department at the Thoraxcenter, Erasmus MC, Rotterdam.
3,693 pubs · 203,211 cites · h-index 199
MD
University of Leuven
1972
PhD
Erasmus University Rotterdam
1986
Established Professor of Interventional Medicine and Innovation
University of Galway · 2020 - Present
Senior Consultant, CORRIB Research Centre
University of Galway · 2020 - Present
Professor of Medicine
Erasmus MC · 2014
Head of Interventional Cardiology Department
Thoraxcenter, Rotterdam · 1997 - 2012
Professor of Interventional Cardiology
Interuniversity Cardiological Institute of the Netherlands (ICIN) · 1988 - Present
Chair and Chief Investigator of the Multivessel TALENT trial · University of Galway
The Multivessel TALENT study establishes the non-inferiority of Supraflex Cruz compared to Synergy, confirming its robust clinical performance in patients with three-vessel disease.
JACC: Cardiovascular InterventionsSerruys et al.
Supports EES over BMS for 10-year POCE/DOCE in STEMI PCI; confirms early TLR reduction sustains superiority without late divergence.
Both sirolimus- and paclitaxel-coated balloons increase angiography-derived microcirculatory resistance immediately after treatment in small coronary vessels, but crystalline paclitaxel-coated balloons result in significantly higher post-procedure resistance and a greater rate of coronary microvascular dysfunction compared to sirolimus-coated balloons.
In this prespecified secondary analysis of the FAVOR III China trial, QFR-guided PCI significantly reduced 3-year MACE compared to angiography-guided PCI in patients with multivessel disease, with consistent directional benefit regardless of MVD status.
3D holography may enable precise membranous septum assessment in TAVI; leaves open whether it reduces pacemaker implantation.
The novel balloon-expandable Myval THV series provides comparable 1-year clinical efficacy to established contemporary THVs in patients with severe symptomatic aortic stenosis.
External validation in a Japanese registry confirms the SYNTAX Score II 2020 accurately predicts 5-year mortality and can aid in identifying which patients with complex coronary disease derive a clear survival benefit from CABG over PCI.
Professor of Interventional Medicine & Innovation, University of Galway · University of Galway
This trial may change our diagnostic and therapeutic approach in the near future. The ESC guidelines recommend a PreTest Probability of CAD prior to any invasive or non-invasive test; the non-inferiority of QFR diagnostic and therapeutic guidance compared to usual care including preprocedural diagnostic tests and periprocedural pressure derived and intravascular imaging may deeply affect our clinical practice and the cost effectiveness of this new approach need to be prospectively evaluated. The easiness of the physiologic assessment post procedure is another major asset of this new approach
European Heart JournalSerruys et al.
Standardizes trial endpoints and grading for paravalvular leak closure devices; extends VARC framework to guide future device evaluation.
Supports similar real-world 30-day stent thrombosis safety; leaves open confirmation versus randomized trials in unrestricted populations.
Antiplatelet therapies retain their established preventive role; leaves open refinement via genomics and predictive factors in future studies.
Angio-IMR methods should not yet replace invasive PW-IMR; leaves open refinement and prospective validation of angiography-based microvascular indices.
Operator visual assessment overestimates device success; core lab QCA flags higher-risk lesions and leaves standardized adjudication open for trial endpoints.
Similar NACE with less major bleeding in subgroup; hypothesis-generating and should not yet change practice in ACS bifurcation lesions.
TAVI demonstrates high procedural success but carries non-negligible complication rates under the updated VARC-3 criteria, with acute kidney injury, bleeding, and non-structural valve dysfunction predicting higher mortality.
Clinical cohort study reveals increased mortality after peri-procedural myocardial infarction in coronary revascularization patients, highlighting the need to minimize procedural injury.
Successful drug-eluting stent implantation for CTO significantly improves left ventricular volumes, and this improvement correlates with the extent of dysfunctional but viable myocardium assessed by pre-procedural MRI.
Lower mean angiography-derived fractional flow reserve (vFFR) is an independent predictor of all-cause death or heart failure hospitalization after TAVI in patients without angiographically significant epicardial stenosis.
